Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)

Inclusion Criteria: * Primary urinary bladder tumor * Secondary urinary bladder tumor (recurrence) * Bipolar or monopolar resection * Creat \<2.2mg/dl * 35% \<Hct \<52% * White bloode cells count WBC ≥3000 / μL * 75000 \<PLT \<500000 / μL * Urine culture: negative / sterile * Alkaline phosphatase, total bilirubin, SGOT, SGPT: values as high as 2 times above the upper normal limit * Good clinical condition (according to Eastern Cooperative Oncology Group PS ≤ 1) * CT Urography without findings suggesting an upper urinary tract tumor in the last 3 months before the transurethral resection of the bladder tumor Exclusion Criteria: * More than 2 low grade / high differentiation (low grade / LG) histologically confirmed bladder tumors in the last 18 months before the transurethral resection of the bladder tumor * High grade / low differentiation (HG) histologically confirmed bladder tumor in the last 9 months before the transurethral resection of the bladder tumor * Those who undergo a transurethral resection of a bladder tumor according to the Guidelines of the European Association of Urology for non-muscle-invasive bladder cancer: incomplete resection of tumor, absence of muscle fibers in the sample with the exception of: Ta / LG-G1, primary Cis and finally, pT1 tumors * Intravesical instillation of chemotherapeutic agent or BCG in the last 6 months before the transurethral resection of the bladder tumor * History of non-urothelial bladder cancer * Stage of disease pT2 (muscle-invasive bladder cancer) * Presence of a tumor in the urethra * Upper urinary tract malignancy (present or anamnestically) * History of pelvic radiotherapy * Histrory of another malignancy in the last 5 years before the transurethral resection of the bladder tumor